Sarepta Therapeutics Inc(SRPT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:45 PM ET (Korea 10/28 05:45)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.9 | Insider Own | 4.91% | Shs Outstand | 105.6M | Perf Week | -1.46% |
| Market Cap | 2.00B | Forward P/E | 54.85 | EPS next Y | -88.83% | Insider Trans | - | Shs Float | 100.4M | Perf Month | 0.48% |
| Enterprise Value | 2.25B | PEG | 0.65 | EPS next Q | 0.07 | Inst Own | 105.47% | Short Float | 22.23% | Perf Quarter | 21.6% |
| Income | -0.27B | P/S | 1.01 | EPS this Y | 143.24% | Inst Trans | 3.76% | Short Ratio | 7.4 | Perf Half Y | -10.35% |
| Sales | 1.97B | P/B | 1.31 | EPS next 5Y | 83.96% | ROA | -7.75% | Short Interest | 22.33M | Perf YTD | -12.22% |
| Book/sh | 14.46 | P/C | 2.53 | EPS past 3/5Y | 3.92% -0.05% | ROE | -18.45% | 52W High | -23.46% ($24.68) | Perf Year | -19.62% |
| Cash/sh | 7.46 | P/FCF | 30.8 | Sales past 3/5Y | 33.06% 32.41% | ROIC | -10.34% | 52W Low | 28.68% ($14.68) | Perf 3Y | -82.32% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -349.84% | Gross Margin | 56.58% | Volatility(W/M) | 5.77% 4.82% | Perf 5Y | -75.56% |
| Dividend TTM | - | EV/Sales | 1.14 | Sales Y/Y TTM | -20.44% | Oper. Margin | -3.15% | ATR (14) | 0.99 | Perf 10Y | -53.71% |
| Dividend Ex-Date | - | Quick Ratio | 2.62 | EPS Q/Q | -102.46% | Profit Margin | -13.48% | RSI (14) | 53.85 | Recom | 2.75 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.42 | Sales Q/Q | -34.34% | SMA20 | 6.25% ($17.78) | Beta | 0.46 | Target Price | $21.64 |
| Payout | - | Debt/Eq | 0.68 | Earnings | 2026/11/5 | SMA50 | -1.8% ($19.24) | Rel Volume | 0.74 | Prev Close | $17.98 |
| Employees | 835 | LT Debt/Eq | 0.68 | EPS/Sales Surpr. | -123.01% 9.51% | SMA200 | 0.67% ($18.76) | Avg Volume(3M) | 3.02M | Price | $18.89 |
| IPO | 1997/6/4 | Option/Short | Yes/Yes | Trades | 12582 | Volume | 2,219,885 | Change | 5.06% |
🧬 This is a US biotech company that develops and commercializes treatments for rare genetic diseases. It commercializes therapies targeting rare inherited muscle disorders such as Duchenne muscular dystrophy, and develops next-generation candidates including gene therapies. With a model that combines revenue-generating commercial products with a gene therapy pipeline, the company is building its presence in the rare genetic disease market.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
Traded less than usual. That is 74% of its average volume.
Next earnings report: November 5
9 days to go.
SRPT has weak earning power
Of every $100 in sales, $3.15 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +143.2% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $101. Peers typically go for $1,213. Compared with its own 1-year average, it is 72% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -75.6%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
22.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #102 of 594 in the industry
Based on market cap of $2B.
SEPN#100 Septerna Inc $2B PER - 
ADRX#101 ADARx Pharmaceuticals Inc $2B PER - SRPT#102 Sarepta Therapeutics Inc $2B PER - 
BRVE#103 Braveheart Bio Inc $2B PER - 
VIR#104 Vir Biotechnology Inc $2B PER - 
FAQ
What kind of company is SRPT?
SRPT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SRPT?
The market cap of SRPT is approximately $2.0B, ranking 2,060 within its sector.
What is the 52-week high and low for SRPT?
SRPT has recorded a 52-week high of $24.68 and a low of $14.68.
